• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Serodiagnostic tests by factor analysis and stepwise discriminating analysis with tumor markers for the detection of ovarian cancer].

作者信息

Kobayashi H, Sumimoto K, Terao T, Kawashima Y

机构信息

Department of Obsterics and Gynecology, Hamamatsu University, School of Medicine.

出版信息

Nihon Sanka Fujinka Gakkai Zasshi. 1989 Dec;41(12):1903-10.

PMID:2480396
Abstract

We measured five tumor markers simultaneously for serodiagnostic testing as a method for the early detection of ovarian cancer. To decrease both false negativity and false positivity in the results of combination assay, statistical analysis including factor analysis and stepwise discriminating function was applied in this study. At least one of these tumor markers was detected as positive in 75.2% (76 of 101 patients) of sera from patients with ovarian cancer before treatment. Six hundred and ninety-three of 7,097 normal sera (9.8%) gave spuriously positive combination assay results. Falsely positive combination assay results were observed in 1,107 of 3,139 patients with benign disease, which could largely be attributed to the high CA125 values in patients with endometriosis. On the basis of factor analysis in order to decrease false positivity, CA125, TPA, and CA125/TPA were selected as the best parameters for distinguishing between ovarian cancer and benign conditions including those pelvic endometriosis showing positive results in combination assays. Subsequently, the function derived by factor analysis made possible the correct classification of 58 of 71 patients with ovarian cancer detected by combination assay, and 84.8% of pelvic endometriosis and benign ovarian tumor subjects were correctly classified into the non-cancer group. Next, in order to decrease false negativity, statistical analysis was also applied. Malignancy could be correctly diagnosed by this procedure in 14 of 25 patients whose tumor was undetectable by combination assay, whereas of subjects without cancer 14.5% were errorenously classified into the ovarian cancer group. In the search for the best method for accurately detecting ovarian cancer, we used image diagnosis (ultrasonography) in combination with serological diagnosis.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
[Serodiagnostic tests by factor analysis and stepwise discriminating analysis with tumor markers for the detection of ovarian cancer].
Nihon Sanka Fujinka Gakkai Zasshi. 1989 Dec;41(12):1903-10.
2
[Field trial of the early detection in patients with ovarian cancer].[卵巢癌患者早期检测的现场试验]
Nihon Sanka Fujinka Gakkai Zasshi. 1989 Nov;41(11):1743-9.
3
[Field trial for the early detection of patients with ovarian cancer--discrimination of ovarian cancer patients by the statistical analysis using Mahalanobis' generalized distance].卵巢癌患者早期检测的现场试验——通过使用马氏广义距离的统计分析鉴别卵巢癌患者
Nihon Sanka Fujinka Gakkai Zasshi. 1992 Feb;44(2):174-80.
4
[Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
Nihon Sanka Fujinka Gakkai Zasshi. 1985 Sep;37(9):1883-92.
5
Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.与CA125、CA19-9、TPA、IAP、CEA和铁蛋白相比,唾液酸化SSEA-1抗原作为卵巢癌肿瘤标志物的临床应用价值。
Nihon Sanka Fujinka Gakkai Zasshi. 1989 Feb;41(2):217-24.
6
[Field trial for the early detection of patients with ovarian cancer].[卵巢癌患者早期检测的现场试验]
Rinsho Byori. 1992 Feb;40(2):139-45.
7
[New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
Ann Ostet Ginecol Med Perinat. 1991 Jan-Feb;112(1):36-40.
8
Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.组织多肽特异性抗原(TPS)在卵巢恶性肿瘤诊断中的准确性。
Anticancer Res. 2000 Mar-Apr;20(2B):1291-5.
9
[Tumor markers of ovarian cancer].
Rinsho Byori. 1992 Apr;40(4):349-53.
10
[Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].唾液和血清CA125检测用于卵巢恶性肿瘤诊断的初步研究
Zhonghua Fu Chan Ke Za Zhi. 1990 Mar;25(2):84-5, 123-4.